Skip to main content
Fig. 5 | Cell & Bioscience

Fig. 5

From: The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment

Fig. 5

Mechanisms of RRM2-Mediated Docetaxel Resistance in Prostate Cancer. A Analysis in the GDSC database indicated that high level of RRM2 decrease the sensitivity of PCA to docetaxel therapy. B, C Drug screening assay in PC3 with RRM2 knockdown. The IC50 values of docetaxel were lower in RRM2 knockdown cells than in the control cells. C RNA-seq analysis in PC3 and DU145 cells after RRM2 knockdown. D RRM2 silencing inhibits the drug metabolism and chemoresistance pathway. F Increase in RRM2 translational expression level in PC3 and DU145 cells after docetaxel treatment in vitro. G Validation of the relationship between RRM2 expression at the translational level and clinical events in clinical samples. H, I RRM2 silencing enhanced the effects of docetaxel in vivo

Back to article page

Cell & Bioscience

ISSN: 2045-3701

Contact us